[Form 4] Helix Acquisition Corp. II Insider Trading Activity
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported an insider acquisition on Form 4 filed for reporting person Wallace Eli M., who is listed as both a director and the Chief Executive Officer. On 08/26/2025 the reporting person acquired a stock option to purchase 499,731 shares at an exercise price of $9.59. The option is subject to a time-based vesting schedule beginning August 11, 2025, with vesting over 48 months and a portion tied to the effectiveness of an S-8 registration; the full grant vests on the fourth anniversary of the vesting commencement date, subject to continued service. The Form 4 was signed by an attorney-in-fact on 08/28/2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT) ha comunicato un'acquisizione da parte di un insider tramite un Form 4, relativo alla persona segnalante Wallace Eli M., indicato sia come amministratore sia come Amministratore Delegato. In data 26/08/2025 la persona segnalante ha acquisito un opzione su azioni per l'acquisto di 499.731 azioni a un prezzo di esercizio di $9,59. L'opzione 猫 soggetta a un piano di maturazione basato sul tempo con decorrenza 11 agosto 2025, che si estende su 48 mesi e include una porzione condizionata all'efficacia di una registrazione S-8; la totalit脿 della concessione matura al quarto anniversario della data di inizio del vesting, subordinata alla permanenza in servizio. Il Form 4 猫 stato firmato tramite procuratore il 28/08/2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT) inform贸 una adquisici贸n por parte de un insider mediante un Form 4 presentado por la persona informante Wallace Eli M., listado como director y Director Ejecutivo. El 26/08/2025 la persona informante adquiri贸 una opci贸n sobre acciones para comprar 499.731 acciones a un precio de ejercicio de $9,59. La opci贸n est谩 sujeta a un calendario de consolidaci贸n basado en el tiempo que comienza el 11 de agosto de 2025, con consolidaci贸n durante 48 meses y una parte condicionada a la efectividad de un registro S-8; la totalidad de la concesi贸n se consolida en el cuarto aniversario del inicio del vesting, condicionado a la continuidad en el puesto. El Form 4 fue firmado por un apoderado el 28/08/2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT)電� 鞚挫偓鞚挫瀽 斓滉碃瓴届榿鞛愳澑 Wallace Eli M.鞐� 雽�頃� Form 4搿� 雮措秬鞛� 旆摑鞚� 氤搓碃頄堨姷雼堧嫟. 氤搓碃鞚胳潃 2025-08-26鞐� 499,731欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞 鞓奠厴鞚� 頄夓偓臧�瓴� $9.59搿� 旆摑頄堨姷雼堧嫟. 頃措嫻 鞓奠厴鞚� 2025雲� 8鞗� 11鞚� 鞁滌瀾霅橂姅 旮瓣皠 旮半皹 臧�靻�(氩犾姢韺�) 鞚检爼鞚� 鞝侅毄霅橂┌ 48臧滌洈鞐� 瓯胳硱 氩犾姢韸鸽悩瓿�, 鞚茧秬電� S-8 霌彪鞚� 須牓 氚滌儩鞐� 鞐半彊霅╇媹雼�; 鞝勳泊 攵�鞐秳鞚� 氩犾姢韺� 臧滌嫓鞚茧攵�韯� 4欤茧厔鞐� 鞕勳爠 氩犾姢韸鸽悩氅� 瓿勳啀 攴茧 臁瓣贝鞚� 攵欖姷雼堧嫟. Form 4電� 2025-08-28鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
BridgeBio Oncology Therapeutics, Inc. (BBOT) a d茅clar茅 une acquisition d'initi茅 sur un Form 4 pour la personne d茅clarante Wallace Eli M., r茅pertori茅e 脿 la fois comme administrateur et directeur g茅n茅ral. Le 26/08/2025, la personne d茅clarante a acquis une option d'achat de 499 731 actions au prix d'exercice de 9,59 $. L'option est soumise 脿 un calendrier d'acquisition bas茅 sur le temps d茅butant le 11 ao没t 2025, avec une acquisition 茅tal茅e sur 48 mois et une partie li茅e 脿 l'entr茅e en vigueur d'un enregistrement S-8 ; la totalit茅 de la subvention devient acquise au quatri猫me anniversaire de la date de d茅but du vesting, sous r茅serve de la continuit茅 de service. Le Form 4 a 茅t茅 sign茅 par un mandataire le 28/08/2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT) meldete einen Insider-Erwerb in einer Form 4 f眉r die meldende Person Wallace Eli M., der sowohl als Direktor als auch als CEO aufgef眉hrt ist. Am 26.08.2025 erwarb die meldende Person eine Aktienoption zum Kauf von 499.731 Aktien zu einem Aus眉bungspreis von $9,59. Die Option unterliegt einem zeitbasierten Vestingplan, der am 11. August 2025 beginnt, sich 眉ber 48 Monate erstreckt und einen Teil umfasst, der an die Wirksamkeit einer S-8-Registrierung gebunden ist; die vollst盲ndige Zuteilung wird am vierten Jahrestag des Vesting-Beginns f盲llig, vorbehaltlich fortgesetzter Dienstzeit. Das Form 4 wurde am 28.08.2025 von einem Bevollm盲chtigten unterzeichnet.
- Insider acquisition disclosed: Reporting person acquired 499,731 stock options on 08/26/2025.
- Alignment with long-term incentives: Options vest over 48 months starting 08/11/2025 and include an S-8 registration contingency.
- None.
Insights
TL;DR: A senior insider received a sizable option grant that aligns compensation with long-term company performance.
The Form 4 discloses an acquisition of 499,731 stock options at a $9.59 exercise price by Wallace Eli M., identified as CEO and director. From a financial viewpoint, the grant size is material relative to a single insider award and will only benefit the holder if the underlying common stock appreciates above $9.59 before expiration. The vesting schedule links realized value to continued service and to an S-8 registration becoming effective for an initial portion, which delays immediate transferability for some shares. This structure commonly aims to retain leadership and tie pay to shareholder value creation.
TL;DR: The disclosure shows a time-vested executive option grant with standard service and registration contingencies.
The filing identifies the reporting person as both director and CEO and documents a grant of 499,731 options exercisable at $9.59 with a four-year vesting schedule beginning August 11, 2025 and a portion contingent on an S-8 filing becoming effective. From a governance perspective, tying vesting to continued service and to registration for resale is a common practice to align executive incentives while managing secondary-market timing. The filing is procedural and provides the required Section 16 disclosure for insider compensation-related transactions.
BridgeBio Oncology Therapeutics, Inc. (BBOT) ha comunicato un'acquisizione da parte di un insider tramite un Form 4, relativo alla persona segnalante Wallace Eli M., indicato sia come amministratore sia come Amministratore Delegato. In data 26/08/2025 la persona segnalante ha acquisito un opzione su azioni per l'acquisto di 499.731 azioni a un prezzo di esercizio di $9,59. L'opzione 猫 soggetta a un piano di maturazione basato sul tempo con decorrenza 11 agosto 2025, che si estende su 48 mesi e include una porzione condizionata all'efficacia di una registrazione S-8; la totalit脿 della concessione matura al quarto anniversario della data di inizio del vesting, subordinata alla permanenza in servizio. Il Form 4 猫 stato firmato tramite procuratore il 28/08/2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT) inform贸 una adquisici贸n por parte de un insider mediante un Form 4 presentado por la persona informante Wallace Eli M., listado como director y Director Ejecutivo. El 26/08/2025 la persona informante adquiri贸 una opci贸n sobre acciones para comprar 499.731 acciones a un precio de ejercicio de $9,59. La opci贸n est谩 sujeta a un calendario de consolidaci贸n basado en el tiempo que comienza el 11 de agosto de 2025, con consolidaci贸n durante 48 meses y una parte condicionada a la efectividad de un registro S-8; la totalidad de la concesi贸n se consolida en el cuarto aniversario del inicio del vesting, condicionado a la continuidad en el puesto. El Form 4 fue firmado por un apoderado el 28/08/2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT)電� 鞚挫偓鞚挫瀽 斓滉碃瓴届榿鞛愳澑 Wallace Eli M.鞐� 雽�頃� Form 4搿� 雮措秬鞛� 旆摑鞚� 氤搓碃頄堨姷雼堧嫟. 氤搓碃鞚胳潃 2025-08-26鞐� 499,731欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞 鞓奠厴鞚� 頄夓偓臧�瓴� $9.59搿� 旆摑頄堨姷雼堧嫟. 頃措嫻 鞓奠厴鞚� 2025雲� 8鞗� 11鞚� 鞁滌瀾霅橂姅 旮瓣皠 旮半皹 臧�靻�(氩犾姢韺�) 鞚检爼鞚� 鞝侅毄霅橂┌ 48臧滌洈鞐� 瓯胳硱 氩犾姢韸鸽悩瓿�, 鞚茧秬電� S-8 霌彪鞚� 須牓 氚滌儩鞐� 鞐半彊霅╇媹雼�; 鞝勳泊 攵�鞐秳鞚� 氩犾姢韺� 臧滌嫓鞚茧攵�韯� 4欤茧厔鞐� 鞕勳爠 氩犾姢韸鸽悩氅� 瓿勳啀 攴茧 臁瓣贝鞚� 攵欖姷雼堧嫟. Form 4電� 2025-08-28鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
BridgeBio Oncology Therapeutics, Inc. (BBOT) a d茅clar茅 une acquisition d'initi茅 sur un Form 4 pour la personne d茅clarante Wallace Eli M., r茅pertori茅e 脿 la fois comme administrateur et directeur g茅n茅ral. Le 26/08/2025, la personne d茅clarante a acquis une option d'achat de 499 731 actions au prix d'exercice de 9,59 $. L'option est soumise 脿 un calendrier d'acquisition bas茅 sur le temps d茅butant le 11 ao没t 2025, avec une acquisition 茅tal茅e sur 48 mois et une partie li茅e 脿 l'entr茅e en vigueur d'un enregistrement S-8 ; la totalit茅 de la subvention devient acquise au quatri猫me anniversaire de la date de d茅but du vesting, sous r茅serve de la continuit茅 de service. Le Form 4 a 茅t茅 sign茅 par un mandataire le 28/08/2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT) meldete einen Insider-Erwerb in einer Form 4 f眉r die meldende Person Wallace Eli M., der sowohl als Direktor als auch als CEO aufgef眉hrt ist. Am 26.08.2025 erwarb die meldende Person eine Aktienoption zum Kauf von 499.731 Aktien zu einem Aus眉bungspreis von $9,59. Die Option unterliegt einem zeitbasierten Vestingplan, der am 11. August 2025 beginnt, sich 眉ber 48 Monate erstreckt und einen Teil umfasst, der an die Wirksamkeit einer S-8-Registrierung gebunden ist; die vollst盲ndige Zuteilung wird am vierten Jahrestag des Vesting-Beginns f盲llig, vorbehaltlich fortgesetzter Dienstzeit. Das Form 4 wurde am 28.08.2025 von einem Bevollm盲chtigten unterzeichnet.
FAQ
What transaction did Wallace Eli M. report on Form 4 for BBOT?
What are the vesting terms for the option grant disclosed in the Form 4?
What positions does the reporting person hold at BridgeBio Oncology Therapeutics?
When was the Form 4 signed and by whom?
What is the exercise price and expiration detail shown for the option?
